The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Bellone, Matteo ^a   Calcinotto, Arianna ^a   Filipazzi, Paola ^b   De Milito, Angelo ^c,d   Fais, Stefano ^c   Rivoltini, Licia ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Active immunotherapy; Adoptive immunotherapy; Anergy; Melanoma; Prostate cancer; T cell

Indexed keywords

CYTOKINE; GAMMA INTERFERON; PROTON PUMP INHIBITOR; T LYMPHOCYTE RECEPTOR;

ACIDITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INVASION; CD8+ T LYMPHOCYTE; CELL PH; CELL THERAPY; CYTOKINE RELEASE; DRUG EFFECT; DRUG PENETRATION; DRUG SAFETY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886945702     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22058     Document Type: Article

References (10)

1. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11:85-95; PMID:21258394; http://dx.doi.org/10.1038/nrc2981.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-9; PMID:15516961; http://dx.doi.org/10.1038/nrc1478.
3. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012; 72:2746-56; PMID:22593198; http://dx.doi. org/10.1158/0008-5472.CAN-11-1272.
4. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96; PMID:17134371; http://dx.doi.org/10.1146/annurev. immunol.25.022106.141609.
5. Henning T, Kraus M, Brischwein M, Otto AM, Wolf B. Relevance of tumor microenvironment for progression, therapy and drug development. Anticancer Drugs 2004; 15:7-14; PMID:15090737; http://dx.doi. org/10.1097/00001813-200401000-00002.
6. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001; 69:522-30; PMID:11310837.
7. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109:3812-9; PMID:17255361; http://dx.doi. org/10.1182/blood-2006-07-035972.
8. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003; 2:132-9; PMID:12563304; http://dx.doi.org/10.1038/ nrd1010.
9. Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolov KR, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today 2009; 14:647-60; PMID:19443264; http://dx.doi.org/10.1016/j. drudis.2009.03.014.
10. Vishvakarma NK, Singh SM. Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: Implication in antitumor activation of tumor-associated macrophages. Immunol Lett 2010; 134:83-92; PMID:20837061; http://dx.doi.org/10.1016/j.imlet.2010.09.002.